Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab?

@article{Ula2015AreNR,
  title={Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab?},
  author={Arife Ulaş and Nilufer Avci and Tugba Fahriye Kos and Erdem Çubukçu and Omer Fatih Olmez and Nilufer Bulut and Mustafa Değirmenci},
  journal={Journal of B.U.ON. : official journal of the Balkan Union of Oncology},
  year={2015},
  volume={20 3},
  pages={714-22}
}
PURPOSE To investigate whether the pretreatment neutrophil lymphocyte ratio (NLR) and the platelet lymphocyte ratio (PLR) have any prognostic significance in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab. METHODS 187 patients were retrospectively analyzed. The patients were separated into two groups according to the mean… CONTINUE READING

Topics

Statistics

0102030201620172018
Citations per Year

Citation Velocity: 7

Averaging 7 citations per year over the last 3 years.

Learn more about how we calculate this metric in our FAQ.